On this Page
THE RISE OF DIY CLINICAL DATA SYSTEMS
WHY MANY STUDIES BEGIN WITH DIY SYSTEMS
Most organizations that rely on Excel or survey tools are not intentionally avoiding
validated systems.
Instead, these decisions are usually driven by practical constraints common in earlystage research organizations.
LIMITED BUDGETS
Early-stage companies often prioritize scientific development over infrastructure investment
SMALL CLINICAL TEAMS
Many startups launch studies with minimal clinical operations staff.
INTERNAL DEVELOPMENT OPTIMISM
Engineering teams may believe internal systems can be built quickly and inexpensively.
LACK OF REGULATORY FAMILIARITY
Executives outside clinical operations may not fully understand regulatory requirements for clinical data systems.
Because of these factors, many studies begin using combinations of general software tools.
Trial Function
Common DIY Tool
Data capture
Excel
Patient surveys
Mailchimp, SurveyMonkey
study documents
study documents
Trial master file
SharePoint
Subject tracking
Internal applications
While this approach may appear workable at the beginning of a study, significant limitations
quickly emerge as research progresses.
REGULATORY RISK: THE HIDDEN COST OF DIY CLINICAL DATA SYSTEMS
One of the most significant risks of using improvised clinical data systems is regulatory
non-compliance.
Clinical trials that support regulatory submissions must follow strict requirements
governing data integrity, traceability, and system validation. These standards are
enforced by regulatory authorities worldwide, including:
- U.S. Food and Drug Administration (FDA)
- Health Canada
- European Medicines Agency (EMA)
- PMDA (Japan)
- MHRA (United Kingdom)
General-purpose tools such as Excel spreadsheets, survey platforms, and cloud file
storage systems were not designed to meet these regulatory standards.
As a result, organizations that rely on these tools may unknowingly expose their studies
to significant regulatory risk.
21 CFR PART 11 COMPLIANCE RISKS
In the United States, electronic records used in FDA-regulated clinical trials must comply
with 21 CFR Part 11
This regulation requires systems to maintain:
- Secure user authentication
- Controlled access to records
- Electronic signatures
- Protection against unauthorized data changes
- Complete audit trails
- Validated system performance
Most general-purpose software tools do not provide these capabilities.
For example:
Trial Function
Common DIY Tool
Data capture
Excel
Patient surveys
Mailchimp, SurveyMonkey
study documents
study documents
Trial master file
SharePoint
Subject tracking
Internal applications
Without these protections, regulators cannot verify who entered data, when
changes were made, or whether records were altered.
This directly undermines the regulatory concept of data integrity.
DATA PRIVACY RISKS (GDPR AND HIPAA)
Clinical trials frequently involve sensitive personal information, including:
- Protected Health Information (PHI)
- Personally Identifiable Information (PII)
- Improvised systems may fail to meet requirements under:
- HIPAA (United States) for PHI protection
- GDPR (European Union) for personal data privacy
- national data protection laws in many jurisdictions
- Improper handling of clinical data can lead to:
- Regulatory investigations
- Financial penalties
- Mandatory breach notifications
- Reputational damage
For multinational trials, compliance must often be demonstrated simultaneously across
multiple regulatory frameworks.
REAL-WORLD CONSEQUENCE: STUDY DATA REJECTION
In some cases, sponsors discover these compliance gaps only after significant data has
already been collected.
When regulators determine that electronic records cannot be trusted due to missing
audit trails or system validation, the data may be considered unreliable for regulatory
submission.
Sponsors may then be required to:
- Repeat data collection
- Reconstruct missing audit trails
- Migrate data into validated systems
- Conduct additional monitoring and verification
- In extreme cases, entire studies may need to be repeated.
The financial impact of repeating a clinical study can exceed millions of dollars, far
surpassing the cost of implementing validated systems at the beginning of the trial.
WHY VALIDATED SYSTEMS EXIST
Purpose-built eClinical platforms are
designed specifically to meet
regulatory expectations.
Validated systems provide:
- Immutable audit trails
- Electronic signatures compliant with 21 CFR Part 11
- Controlled user access and permissions
- System validation documentation
- Secure data storage and encryption
These capabilities ensure that clinical data
remains traceable, auditable, and
defensible during regulatory inspections.
They are a fundamental requirement for
regulatory acceptance of study data.
DATA INTEGRITY CHALLENGES
DATA QUALITY AND DATA INTEGRITY RISKS
Clinical trial data must be accurate, traceable, and auditable.
General-purpose software tools lack built-in mechanisms that ensure data
integrity.
Common issues include:
- Inconsistent data formatting
- Manual transcription errors
- Missing fields or incomplete records
- Difficulty tracking changes to data
These issues often lead to extended data cleaning cycles and delayed database
lock.
Modern electronic data capture systems address these challenges through
structured data entry and configurable validation rules.
These validation rules automatically identify potential errors during data entry,
significantly reducing downstream data cleaning requirements.